Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
Key facts
- Who runs it
- University of Milan
- Where
- Italy3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 220 people, planned
- Started
- 15 Nov 2025
- Ended
- 1 Jul 2026
- Type of study
- Interventional
- Treatments tested
- to improve clinical practice in treatment of non-infective uveitis
- Record updated
- 3 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Diagnosis of non-infectious uveitis in at least one eye with incomplete or not sustained response to topic or systemic steroids at the baseline visit
- Evidence of anterior chamber inflammation to optimize lab sensibility
- As per clinical practice eligibility to receive one of the following immunosuppressive treatment: mycophenolate mofetil (MMF), methotrexate (MTX), azatioprine (AZA), adalimumab (ADA)
- Ability to provide informed consent
Who cannot take part
- Concomitant immunosuppressive treatment
- Presence of other systemic pathologies that do not allow immunosuppressive therapies
- Any ocular or systemic condition that could interfere with cytokine profile expressions
- Ocular media opacities that could interfere with a good quality of fundus exam and/or imaging of the eye
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multicenter, prospective, interventional, non-pharmacological study aims to investigate whether the intraocular cytokine profile is associated with the therapeutic response to immunosuppressive drugs in patients with non-infectious uveitis (NIU). Approximately 220 patients with NIU in at least one eye, showing inadequate response to topical or systemic corticosteroids at baseline and presenting with signs of anterior segment inflammation, will be enrolled to enhance sensitivity to laboratory assays. Aqueous humor and blood samples will be collected at baseline. Cytokine concentrations of 14 different cytokines will be measured using multiplex immunoassay techniques. Participants will receive immunosuppressive treatment based on standard clinical practice.
The group in the trial
- Patients affected by non-infective uveitisTreatment being tested
Those patients will be recruited from the routine clinical practice. The treatment choice is not pre-planned but it will be based on the treating physician's clinical decision.
Treatment: to improve clinical practice in treatment of non-infective uveitis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 3 December 2025